Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety
and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and
adolescent patients 12 to 17 years of age, inclusive, with clinically diagnosed GERD. The
treatment period will be up to 8 weeks.